⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SVRA News
Savara Inc.
Form 8-K
sec.gov
SVRA
Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update
businesswire.com
SVRA
Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
businesswire.com
SVRA
Savara Announces Participation in 2026 Citizens Life Sciences Conference
businesswire.com
SVRA
Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
businesswire.com
SVRA
Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
businesswire.com
SVRA
Savara Announces New Employment Inducement Grant
businesswire.com
SVRA
Savara Announces Participation in Upcoming Investor Healthcare Conferences
businesswire.com
SVRA
SAVARA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Savara, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
globenewswire.com
SVRA
Savara Announces New Employment Inducement Grant
businesswire.com
SVRA